| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., November 5, 2026 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, tod... |
| 02 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., August 12, 2026 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, toda... |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
We have acted as counsel to Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the offering by the Company shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate ... |
| 28 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 13 May 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
SOUTH SAN FRANCISCO, Calif., May 13, 2026 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today p... |
| 15 Apr 2026 |
8-K: Other Events
As representatives (the “Representatives”) of the several Underwriters |
| 13 Apr 2026 |
8-K: Other Events
On April 13, 2026, Allogene Therapeutics, Inc. (the “Company”) announced the commencement of a proposed underwritten public offering of its common stock. |
| 13 Apr 2026 |
8-K: Other Events
On April 13, 2026, Allogene Therapeutics, Inc. (“Allogene” or the “Company”) announced interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (“cema-cel”) in first-line (“1L”) consolidation for lar... |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., March 12, 2026 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., November 6, 2025 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, to... |
| 14 Oct 2025 |
8-K: Other Events
On September 26, 2025, Factor Bioscience Inc. (“Factor”) filed a complaint in the United States District Court for the District of Delaware against our gene-editing technology licensor, Cellectis S.A., and its affiliate Cellectis, Inc. (... |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., August 13, 2025 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, tod... |
| 01 Aug 2025 |
8-K: Other Events
On August 1, 2025, Allogene Therapeutics, Inc. (the “Company”) announced that it has selected standard fludarabine and cyclophosphamide (“FC”) as the lymphodepletion regimen to be used in its ALPHA3 study evaluating cemacabtagene anseged... |
| 23 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2025, Allogene Therapeutics, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 22, 2025, the record date for the Annual Meeting, 218,705,245 shares of common stock were outs... |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., May 13, 2025 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today ... |
| 13 Mar 2025 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., March 13, 2025 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, toda... |
| 25 Feb 2025 |
8-K: Entry into a Material Definitive Agreement
On February 19, 2025, Allogene Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Strategic Collaboration Agreement (the “Amended Agreement”) with Foresight Diagnostics, Inc. (“Foresight”), which amended and restated... |
| 29 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 13 Nov 2024 |
8-K: Other Events
On November 11, 2024, Allogene Therapeutics, Inc. (the “Company”) decided to discontinue enrollment in its Phase 1 cohort in the ALPHA2 clinical trial to evaluate cemacabtagene ansegedleucel (“cema-cel”) as a treatment for relapsed or re... |
Loading...